Injection
Sermorelin Injection
A growth hormone-releasing peptide that supports deeper sleep, faster recovery and lean muscle by working with your body's own rhythm.
Starting at $179/mo
Growth hormoneRecovery & sleep
CJC-1295 / Ipamorelin
RxPrescription onlyInjected under the skin · 5 days a week · 0.24 mg · Growth hormone · Recovery & sleep
Starting at $229/mo
Two peptides that prompt your pituitary to release more of your own growth hormone in its natural pulses, used for recovery, deeper sleep and body composition.
Choose your plan
Real prices from our pharmacy. Longer plans cost less per month and are billed up front. Pause or cancel anytime.
- Supports your own growth hormone rhythm, without synthetic HGH
- Deeper sleep and recovery are usually the first changes
- Nightly subcutaneous injection, dosed by your physician
Every plan includes
- Personalized, physician-guided plan
- Monthly, 3-month and 6-month plans
- Dispensed by a US-licensed compounding pharmacy
- Unlimited protocol adjustments and messaging
- Ongoing support and check-ins
- Pause or cancel anytime
- Reviewed by our in-house physicians
- Physician-guided care
- Ongoing, expert support
- 100% online
- Free, discreet shipping
What is CJC-1295 / Ipamorelin?
(a GHRH analog paired with a selective secretagogue)
CJC-1295 is a modified version of growth hormone-releasing hormone (GHRH) that keeps the signal to your pituitary active for longer. Ipamorelin acts on a second receptor (the ghrelin receptor) to release growth hormone selectively, with little effect on cortisol or prolactin. Together they raise the size of your own natural growth-hormone pulses rather than replacing them.
- How it is taken
- Injected under the skin
- How often
- 5 days a week
- Dose range
- 0.24 mg
- Form
- Growth hormone · Recovery & sleep
1998
the year ipamorelin was described as the first selective growth hormone secretagogue
CJC-1295 raised growth hormone and IGF-1 for days after a single dose in a controlled human study. Compounded CJC-1295 / ipamorelin is prescribed off-label at your physician's discretion.
How it works,
week by week.
Day 1
A US-licensed physician reviews your goals, history and, when needed, IGF-1 and metabolic labs, and sets your dose. The kit includes everything you need.
Week 1–2
A small subcutaneous injection, usually at night so it lines up with your body's own growth-hormone pulse. Deeper sleep is often the first thing people notice.
Month 1–2
Energy and recovery from training tend to improve next. Your physician checks in and adjusts the dose if needed.
Month 3–6
Body-composition changes take longer: less abdominal fat and more lean mass with consistent training and nutrition.
Beyond
Your physician decides with you how to continue, cycle or pause, guided by labs and how you feel.
What you may notice,
and when.
Deeper sleep
usually the first change people report
Steadier energy
through the day, without stimulants
Recovery and lean mass
with training, over months
Body composition
gradual, and strongest with tesamorelin for abdominal fat
Individual results vary. Benefits reflect what Zepym Health members commonly report to their physician at check-ins; they are not the results of a clinical trial.
Safety first:
what to know before you start.
Important safety information and common side effects
Growth hormone-releasing peptides are generally well tolerated. Common, mild effects include redness or a small bump at the injection site, headache, flushing, water retention, tingling in the hands or joint aches in the first weeks, and vivid dreams as sleep deepens. They are not prescribed with an active cancer, a cancer under evaluation, uncontrolled diabetes, or during pregnancy or breastfeeding, and they are used with care in people with a history of pituitary disease. MOTS-c may change blood sugar responses: tell your physician if you take diabetes medication. Stop and seek care for hives, swelling of the face or lips or trouble breathing. Tell your physician about every medication you take.
The research behind
CJC-1295 and ipamorelin.
Two growth-hormone-releasing peptides. CJC-1295 has a short human Phase 1 study; ipamorelin has been studied mainly in animals.
- Healthy adults2 to 10-fold GH rise
In two randomized, placebo-controlled trials in healthy adults aged 21 to 61 (28 and 49 days), growth hormone rose 2- to 10-fold for six days or more after subcutaneous CJC-1295, and IGF-I rose 1.5- to 3-fold for 9 to 11 days. No serious adverse reactions were reported.
Teichman et al., J Clin Endocrinol Metab 2006 - Ipamorelinanimal data
Raun et al. (1998) describe ipamorelin as a selective growth hormone releaser. In animal studies it released growth hormone without raising ACTH or cortisol. It is an animal study, not a human trial.
Raun et al., Eur J Endocrinol 1998 - Efficacyno efficacy trials
We found no published Phase 2 or Phase 3 trial showing a clinical benefit of the combination in any condition. The 2006 study measured hormone levels, not outcomes.
Teichman et al., J Clin Endocrinol Metab 2006
What the studies found
- Raises growth hormone 2- to 10-fold for six days or more in healthy adults (Teichman, J Clin Endocrinol Metab 2006). This is a hormone effect, not a clinical outcome.
- Raises IGF-I 1.5- to 3-fold for 9 to 11 days in healthy adults (Teichman, J Clin Endocrinol Metab 2006).
- No human trial has measured a health benefit such as body composition, recovery or sleep, so none is shown.
- In animal studies, ipamorelin released growth hormone without raising ACTH or cortisol (Raun et al., Eur J Endocrinol 1998).
The 2006 trial studied CJC-1295, a long-acting form, in healthy people over several weeks. Hormone responses are averages from research subjects, not predictions for anyone. Ipamorelin has no published controlled human trial in this review. Compounded versions were not studied.
What this does not say
- No human trial measured body composition, recovery, sleep or any health outcome for this combination.
- The studied adults were healthy; the effects of long-term use in people with other conditions are not known.
- Growth hormone raises IGF-I, and the long-term effects of sustained elevation are not established.
The research
behind it.
In healthy adults, CJC-1295 raised growth hormone 2- to 10-fold and IGF-1 1.5- to 3-fold, with effects lasting about a week after one injection.
Ipamorelin releases growth hormone selectively, without the cortisol and prolactin rise seen with older secretagogues. Your physician sets the dose and follows IGF-1 and how you feel.
Getting started
takes a few minutes.
- 1
Connect with a physician
Answer a few questions online and a US-licensed physician reviews your health, history and goals to make sure treatment is right for you. 100% online. No in-person visit required.
- 2
Get your discreet shipment
If approved, your treatment is compounded by a US-licensed, LegitScript-certified pharmacy, inspected for quality, and shipped discreetly to your door.
- 3
Receive continuous support
Start with one goal, then keep building over time. Unlimited physician messaging, easy refills and dose adjustments, all from the Zepym Health app.
Frequently asked questions
Contact supportHow do I use CJC-1295 / Ipamorelin?
Injected under the skin, 5 days a week, at bedtime. The starting prescription is 20 units (0.24 mg) each time. Your physician sets your own dose and it is printed on your label.
What exactly is in it?
CJC-1295, Ipamorelin.
How much arrives in each shipment?
1 vial at the starting strength, shipped to your door from a licensed US pharmacy.
How is this different from sermorelin?
Sermorelin is a shorter-acting GHRH analog. CJC-1295 keeps the GHRH signal active longer, and ipamorelin adds a second, selective pathway. Many people describe a stronger effect on sleep and recovery; your physician decides which fits your goals and history.
How do I take it?
A small subcutaneous injection with an insulin-style needle, most often at night before bed, on an empty stomach. Your physician sets the dose and schedule; MOTS-c is often a few times a week rather than nightly. The kit includes everything.
Is this the same as HGH?
No. These peptides prompt your pituitary to release your own growth hormone in its natural pulses, so the body's feedback loops stay in control. Synthetic HGH bypasses those loops. That difference is why the side-effect profile is milder.
What are the side effects?
Mild for most people: injection-site redness, headache, flushing, water retention, tingling or joint aches in the first weeks, and vivid dreams. Not prescribed with an active or suspected cancer or in pregnancy. Read the safety information above.
CJC-1295 / Ipamorelin educational content reviewed by our physician
Scott Nass, MD Doctor of Medicine, board-certified in Family Medicine
Charles R. Drew University and David Geffen School of Medicine at UCLA. Family Medicine residency at Ventura County Medical Center.
More options
in this area.
Injection
Tesamorelin
A peptide that targets stubborn abdominal fat and supports a leaner body composition, prescribed and monitored by a licensed clinician.
Starting at $179/mo
Troche
Sermorelin Troches
The same growth hormone-releasing peptide as a dissolving troche, for people who would rather skip injections.
30 troches per month
Starting at $209/mo
Injection
BPC-157
A peptide studied for tissue repair and recovery, used to support healing of muscle, tendon and gut after injury or hard training. Prescribed and dosed by a licensed physician.
Starting at $209/mo
References
- 1.Ipamorelin, the first selective growth hormone secretagogue: release of growth hormone without cortisol or prolactin. Eur J Endocrinol, 1998
- 2.Prolonged stimulation of growth hormone and IGF-1 secretion by CJC-1295 in healthy adults. J Clin Endocrinol Metab, 2006
- 3.Sermorelin: a better approach to management of adult-onset growth hormone insufficiency? Clin Interv Aging, 2006
- 4.The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metab, 2015
- 5.Metabolic effects of a growth hormone-releasing factor (tesamorelin): randomized trial showing reduced visceral fat. N Engl J Med, 2007
- 6.Effects of tesamorelin on non-alcoholic fatty liver disease: randomised, double-blind, multicentre trial. Lancet HIV, 2019
Prescription products require an online evaluation with a licensed medical professional who will determine if a prescription is appropriate. Products are compounded by a licensed pharmacy. The FDA has not reviewed or approved compounded products for any use for safety, efficacy, or quality. Compounded medications are not FDA-approved brand-name products.